Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, LL-37 is a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586.
FOXO4-DRI is amino acids long, whereas LL-37 is longer as it has a length of 37 amino acids. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset. LL-37 is made up of a sequence of Leucine, Leucine, Glycine, Aspartic acid, Phenylalanine, Phenylalanine, Arginine, Lysine, Serine, Lysine, Glutamic acid, Lysine, Isoleucine, Glycine, Lysine, Glutamic acid, Phenylalanine, Lysine, Arginine, Isoleucine, Valine, Glutamine, Arginine, Isoleucine, Lysine, Aspartic acid, Phenylalanine, Leucine, Arginine, Asparagine, Leucine, Valine, Proline, Arginine, Threonine, Glutamic acid, Serine.
FOXO4-DRI
Intracellular target is the FOXO4–p53 protein–protein interaction interface; it does not signal via a traditional cell-surface receptor38
LL-37
FOXO4-DRI
FOXO4
LL-37
CAMP
No related articles are linked to these peptides yet.